BTX
BlackRock Technology and Private Equity Term TrustNYSEFINANCIAL SERVICESASSET MANAGEMENT
Key Statistics
Market Cap
$828.64M
P/E Ratio
19.19
EPS
$0.37
Beta
—
52W High
$7.10
52W Low
$5.07
50-Day MA
$6.57
200-Day MA
$6.85
Dividend Yield
0.00%
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About BlackRock Technology and Private Equity Term Trust
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-25.72M |
| Operating Margin | 0.00% |
| Return on Equity | -427.20% |
| Return on Assets | -35.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.26 |
| Price-to-Book | 0.85 |
| Price-to-Sales (TTM) | 68.10 |
| EV/Revenue | 68.1 |
| EV/EBITDA | 0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $116.71M |
| Float | $34.05M |
| % Insiders | 0.00% |
| % Institutions | 23.27% |
Historical Volatility
HV 10-Day
40.04%
HV 20-Day
34.46%
HV 30-Day
31.81%
HV 60-Day
28.54%
HV Rank
85.3%
Volatility is currently expanding
Data last updated: 4/10/2026